Skip to main content

Call for papers - Cell and molecular therapy for cardiovascular disorders

Guest Editors:
Sherin Saheera: University of Massachusetts Chan Medical School, US
Huiliang Zhang: University of Arkansas for Medical Sciences, US

Submission Status: Open   |   Submission Deadline: 21 June 2024

BMC Cardiovascular Disorders is calling for submissions to our Collection on Cell and molecular therapy for cardiovascular diseases. Scientists from around the globe are investigating/leveraging cell and molecular-based strategies to protect, regenerate, replace, and restore the function of cardiac and vascular tissue. Advances in basic and clinical research have yielded encouraging findings highlighting the promise of such strategies to treat a range of CVDs. However, gaps in our knowledge remain and further research is required to translate findings from basic research into the clinic. 


New Content ItemThis Collection supports and amplifies research related to SDG 3: Good Health & Wellbeing.

Meet the Guest Editors

Back to top

Sherin Saheera: University of Massachusetts Chan Medical School, US

Dr Sherin Saheera completed her PhD in India in 2017 and went to the US to pursue her postdoctoral studies. After a year of training at the University of Alabama at Birmingham, she is currently working as a Postdoctoral Associate at the University of Massachusetts, Chan Medical School, where she has been  since January 2019. She has over 18 publications in peer reviewed high impact journals and has been serving as an editorial board member and reviewer for reputed journals. She has also presented papers in several national and international conferences.

Huiliang Zhang: University of Arkansas for Medical Sciences, US

Dr Zhang’s research focuses on cardiac dysfunction in the aging heart with an emphasis on the pathogenic role of elevated proton leak from mitochondria. He explores the strategies for restoring mitochondrial function and stem cell therapies to reverse cardiac dysfunction in preclinical models of aging. Dr. Zhang is the principal investigator of the NIH R35 grant and the American Heart Association (AHA) Career Development Award. Dr. Zhang served in NIH and AHA study sections. He has nearly 40 original publications and has won several national trainee and junior faculty awards.

About the Collection

BMC Cardiovascular Disorders is calling for submissions to our Collection on Cell and molecular therapy for cardiovascular diseases. Scientists from around the globe are investigating/leveraging cell and molecular-based strategies to protect, regenerate, replace, and restore the function of cardiac and vascular tissue. Advances in basic and clinical research have yielded encouraging findings highlighting the promise of such strategies to treat a range of CVDs. However, gaps in our knowledge remain and further research is required to translate findings from basic research into the clinic. 

In support of SDG 3: Good Health & Wellbeing, BMC Cardiovascular Disorders calls for papers exploring the potential of stem cells, gene editing, tissue engineering, disease modeling, and organoids to improve our understanding of cardiovascular diseases and open new avenues for therapeutic intervention. 

Image credit: Andrii Yalanskyi / stock.adobe.com

  1. Myocardial ischemia is a prevalent cardiovascular disorder associated with significant morbidity and mortality. While prompt restoration of blood flow is essential for improving patient outcomes, the subsequen...

    Authors: Zhian Chen, Tianying Liu, Hao Yuan, Han Sun, Sitong Liu, Shuai Zhang, Li Liu, Shuang Jiang, Yong Tang and Zhi Liu
    Citation: BMC Cardiovascular Disorders 2024 24:183
    Content type: Research Published on:

  2. Atherosclerosis(AS) poses a pressing challenge in contemporary medicine. Formononetin (FMN) plays a crucial role in its prevention and treatment. However, the detailed impact of FMN on the stability of atheros...

    Authors: Ying He, Youde Cai, Dingling Wei, Liping Cao, Qiansong He and Yazhou Zhang
    Citation: BMC Cardiovascular Disorders 2024 24:121
    Content type: Research Published on:

  3. This study evaluates the effectiveness of a combined regimen involving injectable hydrogels for the treatment of experimental myocardial infarction.

    Authors: Han Gao, Song Liu, Shanshan Qin, Jiali Yang, Tian Yue, Bengui Ye, Yue Tang, Jie Feng, Jun Hou and Dunzhu Danzeng
    Citation: BMC Cardiovascular Disorders 2024 24:119
    Content type: Research Published on:

  4. The pathogenesis of cardiac arrhythmias is multifaceted, encompassing genetic, environmental, hemodynamic, and various causative factors. Emerging evidence underscores a plausible connection between gut flora,...

    Authors: Kaiyuan Li, Peng Liu, Miao Liu, Jun Ye and Li Zhu
    Citation: BMC Cardiovascular Disorders 2024 24:38
    Content type: Research Published on:

  5. The key complication of myocardial infarction therapy is myocardial ischemia/reperfusion injury (MI/RI), and there is no effective treatment. The present study elucidates the mechanism of action of lncRNA KCNQ...

    Authors: Tongcai Tan, Liang Tu, Yanmei Yu, MinJie He, Xingchao Zhou and Lei Yang
    Citation: BMC Cardiovascular Disorders 2024 24:19
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Cell and molecular therapy for cardiovascular disorders" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.